Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1/2 2Phase 1 2Phase NA 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Gastrointestinal Stromal Tumors 2

Interventions

Imatinib Mesylate 4ripretinib 2pexidartinib 2binimetinib 2Sunitinib 2tinostamustine 1spartalizumab 1pembrolizumab 1avapritinib 1Radiotherapy 1Injections 1HhAntag691 1Gemcitabine 1Everolimus 1Drug Therapy 1Blood Specimen Collection 1Biopsy 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Gastrointestinal Stromal Tumors × ripretinib × Clear all
NCT05957367 2026-06-02

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Deciphera Pharmaceuticals, LLC

Phase 1/2 Recruiting
94 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05080621 2022-01-05

Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

Deciphera Pharmaceuticals, LLC

Phase 1/2 Withdrawn
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡